/PRNewswire/ V-Wave today announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American College of Cardiology s (ACC).
ACC announces late-breaking clinical trial lineup for 2024 Scientific Session healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
NEW ORLEANS — In the STOP-CA trial, prophylactic atorvastatin therapy reduced the occurrence of anthracycline-associated left ventricular dysfunction at 12 months among patients who underwent treatment for Hodgkin and non-Hodgkin lymphoma.“Anthracyclines are a standard chemotherapy drug used in the treatment of breast cancer and lymphoma. Anthracyclines are prescribed to more than 1
NEW ORLEANS — Treatment of severe tricuspid regurgitation with transcatheter repair was safe, reduced severity of tricuspid regurgitation and led to improvements in quality of life at 1 year, according to results of the TRILUMINATE Pivotal trial.
“[The] TRILUMINATE Pivotal [trial] is a pioneering study as the first randomized clinical trial in this unique population of patients with
NEW ORLEANS — In the CLEAR Outcomes trial, bempedoic acid reduced risk for major CV events by 13% compared with placebo, including a 23% lower risk for MI, among adults with a history of CVD or at high risk deemed statin intolerant.Bempedoic acid (Nexletol, Esperion Therapeutics) was FDA approved in 2020 for lowering LDL, but the effects of the drug on CV outcomes have not been assessed,